A 12-week international, multicenter, open label, non-comparative study to evaulate the feasibility of switching any antipsychotic treatment to sustained-release quetiapine fumarate (Seroquel) in patients with schizophrenia

Trial Profile

A 12-week international, multicenter, open label, non-comparative study to evaulate the feasibility of switching any antipsychotic treatment to sustained-release quetiapine fumarate (Seroquel) in patients with schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jan 2013

At a glance

  • Drugs Quetiapine (Primary) ; Antipsychotics
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 29 Apr 2009 Cost-utility analysis based on this study published in Current Medical Research and Opinion, Mar, 2009.
    • 31 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top